Date: 2017-05-15
Type of information: Series A financing round
Company: BiomX (Israel)
Investors: Johnson & Johnson Development Corporation (USA - NJ) Mirae Asset Global Investments (Republic of Korea) Orbimed (USA – NY) SBI (Japan) Seventure Partners (France) Takeda Ventures (Japan)
Amount: €24 million
Funding type: series A financing round
Planned used:
- BiomX, previously named MBcure, was founded in the FutuRx incubator, with the support of the Israel Innovation Authority. The company focuses on developing novel therapeutics to alleviate human diseases stemming from dysbiosis of the microbiome. It offers a complete end-to-end solution from target discovery to development of therapeutic compounds, with flexible capabilities to precisely modulate the microbiome and restore microbial balance through adding or eradicating bacteria with both native and synthetically altered phages (viruses that attack bacteria).
- BiomX’s microbiome modulation technologies are based on research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
- The therapeutic pipeline consists of products for the treatment of acne, Inflammatory Bowel Disease (IBD), cancer, and therapeutics that modulate the microbiome for improved performance of immuno-oncology drugs. Proceeds from the round will be used to advance this pipeline towards clinical stages and to continue enhancing BiomX’s proprietary microbiome modulation platform technologies.
Others: • On May 15, 2017, BiomX announced that it has successfully secured $24 million in a Series A financing. The round was led by OrbiMed, Johnson & Johnson Innovation – JJDC and Takeda Ventures, with participation from Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors.
Therapeutic area:
Is general: Yes
